ALC Alcon Inc.

Alcon Shareholders Approve All Proposed Resolutions at the 2020 Annual General Meeting

Alcon Inc. (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced shareholder approval of all resolutions proposed at its 2020 Annual General Meeting.

Given the global COVID-19 outbreak, Alcon previously directed shareholders to send their voting instructions to the independent representative, Hartmann Dreyer Attorneys-at-Law. Shareholders showed a high level of interest and engagement in the resolutions proposed, with a total of 346,070,177 Alcon Inc. shares, corresponding to 70.76% of the shares entitled to vote, represented.

Shareholders re-elected Mike Ball as Chairman of the Board of Directors, and all members of the Board who stood for re-election, namely Lynn Bleil, Arthur Cummings, David Endicott, Thomas Glanzmann, D. Keith Grossman, Scott Maw, Karen May, Ines Pöschel, Dieter Spälti, for a term of one year. In addition, shareholders re-elected Thomas Glanzmann, Keith Grossman, Karen May and Ines Pöschel to form the Compensation Committee for a term of one year. The Board today designated Karen May as the Chairman of the Compensation Committee with her re-election. Discharge was granted to the members of the Board of Directors and the members of the Executive Committee for the 2019 financial year.

In two separate binding votes, shareholders approved the maximum aggregate amount of compensation of the Board of Directors for the next term of office ending at the 2021 Annual General Meeting, and the Executive Committee for 2021. Shareholders also accepted the 2019 Compensation Report.

Alcon shareholders approved the operating and financial review of Alcon Inc., the annual financial statements of Alcon Inc. and the consolidated financial statements for 2019. Shareholders also approved that, after an allocation of CHF 9,784,000 to the general reserve, the remaining amount of available earnings be carried forward.

PricewaterhouseCoopers SA, Geneva, was re-elected as statutory auditors for the 2020 financial year. Hartmann Dreyer Attorneys-at-Law was re-elected as the independent representative for a term of one year extending until the 2021 Annual General Meeting.

Alcon will announce its first quarter 2020 earnings on May 12 after the close of the US markets, with an investor call scheduled for May 13.

About Alcon

Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning more than seven decades, we offer the broadest portfolio of products to enhance sight and improve people’s lives. Our Surgical and Vision Care products touch the lives of more than 260 million people in over 140 countries each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors. Our more than 20,000 associates are enhancing the quality of life through innovative products, partnerships with eye care professionals and programs that advance access to quality eye care. Learn more at .

Connect with us on



EN
06/05/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Alcon Inc.

 PRESS RELEASE

Alcon Publishes Agenda for 2024 Annual General Meeting

GENEVA--(BUSINESS WIRE)-- Alcon (SIX/NYSE: ALC), the global leader in eye care, will hold its Annual General Meeting (AGM) on May 8, 2024. Alcon is pleased to welcome shareholders to its second in-person AGM since becoming an independent, standalone company. The company looks forward to hearing directly from its shareholders at this open format meeting. The agenda for this 2024 AGM consists of the regular items, as well as, newly, the vote on the 2023 Report on Non-Financial Matters. The invitation to the AGM, including explanatory information on individual agenda items, will be publishe...

 PRESS RELEASE

Alcon Strengthens Leadership in IOL Innovation with the launch of the ...

BENGALURU, India--(BUSINESS WIRE)-- Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the launch of the Clareon® Family of intraocular lenses (IOLs) in India. Utilizing Alcon’s most advanced IOL material in its 20+ years of IOL innovation, Clareon delivers consistent visual outcomes and exceptional clarity that lasts.°,12-18 Clareon’s clarity is born out of a glistening-free§ IOL material that has among the lowest levels of haze and subsurface nanoglistenings (SSNGs), compared to leading competitor IOLs.†,*,12-14 The Clareon pla...

 PRESS RELEASE

Vivity, the World’s Leading EDOF IOL, Reaches One Million Milestone

TORONTO--(BUSINESS WIRE)-- Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today proudly announces AcrySof® IQ Vivity® and Clareon® Vivity extended depth of focus (EDOF) intraocular lens (IOL) has surpassed more than one million implants worldwide. Vivity is the most implanted EDOF IOL globally.1* Alcon is the global leader in IOLs—every four seconds an eye is implanted with an Alcon IOL—and continues to innovate in this space to address patients’ unmet needs.5¤ “Reaching the one million milestone for Vivity, the world's leading EDOF IOL, rep...

 PRESS RELEASE

Vivity, la LIO à profondeur focale accrue première au monde, atteint u...

TORONTO--(BUSINESS WIRE)-- Alcon (SIX/NYSE : ALC), le chef de file mondial en matière de soins oculaires qui se consacre à aider les gens à voir brillamment, annonce aujourd’hui fièrement que les lentilles intraoculaires (LIO) à profondeur focale accrue AcrySofMD IQ VivityMD et ClareonMD Vivity ont dépassé plus d’un million d’implants dans le monde. Vivity est la LIO à profondeur focale accrue la plus implantée à l’échelle mondiale.1* Alcon est le chef de file mondial dans le domaine des LIO – toutes les quatre secondes une LIO Alcon est implantée – et continue d’innover dans ce domaine pour r...

 PRESS RELEASE

Vivity, the World’s Leading EDOF IOL, Reaches One Million Milestone

FORT WORTH, Texas--(BUSINESS WIRE)-- Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today proudly announces AcrySof® IQ Vivity® and Clareon® Vivity extended depth of focus (EDOF) intraocular lenses (IOLs) have surpassed more than one million implants worldwide. Vivity is the most implanted EDOF IOL globally.1* Alcon is the global leader in IOLs—every four seconds an eye is implanted with an Alcon IOL—and continues to innovate in this space to address patients’ unmet needs.5 “We are proud to celebrate the one million Vivity eyes empowering ca...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch